Dedicated Tracks to MOVE WITH CERTAINTY THROUGH DRUG DEVELOPMENT
Track 1: Seeing Further in Discovery and Non-Clinical Research
Drug discovery follows a Design-Make-Test-Analyze cycle, where each new set of assay results and in silico predictions inform the next generation of compound candidates. Learn how informatics and GPTs are accelerating this cycle, freeing scientists to focus on the innovative leaps required to advance new leads. Then, see how the combination of quantitative systems toxicology and on-demand visualization of SEND datasets can identify potential off-target effects and adverse events sooner. 
Ideal for: VP of R&D, Head of Chemistry, Head of Biology, Lead Toxicologist, Lead Pathologist
Track 2: Latest Advances in MIDD: Insights, Examples and Perspectives
This track highlights innovative approaches in Model-Informed Drug Development (MIDD) to optimize drug development processes. Topics include the evolving regulatory landscape with the draft ICH M15 guidance, the application of Quantitative Systems Pharmacology (QSP) and Physiologically-Based Pharmacokinetic (PBPK) modeling for oncology therapies, and novel techniques for dose optimization. Experts will also discuss challenges in Phase II dosing and explore emerging technologies such as machine learning to enhance pharmacokinetic modeling accuracy.
Track 3: Clinical Data Flow for Faster Analysis and Submission
Automating the flow of clinical data from source to CDISC deliverables accelerates both analysis and submission. Explore the technologies and meet the teams that will make this possible, as we examine metadata repositories, data transfer processes with automated error checking, and collaborative validation platforms. 
Ideal for: VP of Biometrics, Head of Data Standards, Head of Data Management, Heads of Biostatistics
Track 4: Drug Development and Regulatory Strategy
Embracing Totality of Evidence throughout your drug development journey
Regulatory agencies are increasingly embracing the Totality of Evidence approach, reshaping drug development strategies and decision-making. Join experts from Certara’s Drug Development Solutions and Regulatory Sciences teams as they discuss this shift in regulatory philosophy, its impact on pharmaceutical development, and how companies can navigate both the challenges and opportunities it presents.
Ideal for all Executives and Leaders